Company intelligence / Profile preview

Opus Instruments

Durham, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Most advanced program OPGx-LCA5 in Phase 1/2 with encouraging early data; OPGx-BEST1 Phase 1/2 initiation expected 2025; Phentolamine Ophthalmic Solution 0.75% in Phase 3; APX3330 Phase 3 SPA agreed with FDA.[1][2][3]

Therapeutic areas: Ophthalmology
Modalities: Gene therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Opus Instruments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opus Instruments.

Explore the full profile